Slide 1: Tempus AI, Inc. Investor Presentation Q2 2025
Tempus AI, Inc. Investor Presentation Q2 2025 August 8th, 2025
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements that reflect Tempus AI, Inc.’s (the “Company” or “Tempus”) current expectations and projections with respect to, among other things, its financial condition, results of operations, plans, objectives, future performance and business. For
Slide 3: Based on recent advancements, including generative AI
Based on recent advancements, including generative AI, the time is now. AI is finally ready to transform healthcare. We believe the change will occur in diagnostics first.
Slide 4: We envision a new approach to precision medicine
ARTIFICIAL We envision a new approach INTELLIGENCE to precision medicine. Unraveling disease complexity from a MULTIMODAL DATA complete, unified picture of the patient Leveraging AI to reveal unmet needs that lead to actionable insights Mobilizing insights through application UNIFIED TOOLING via a co
Slide 5: Through our sequencing efforts and established connections
Through our sequencing efforts and established connections with >4,500 institutions, we >40,000,000 have amassed one of largest total patient records proprietary datasets in the world Allowing us to build and train AI models and distribute the insights generated to >2,000,000 treating physicians, pa
Slide 6: Tempus' three product lines are integrated and benefit from network effects
Tempus’ three product lines are integrated and benefit from network effects GENOMICS Our Platform supports our three product Diagnostic Testing lines, with each designed to enable and Run tests and bill enhance the others, thereby translating the insurance or be paid directly network effects of our t
Slide 7: The Genomics product line focuses on delivering intelligent results
GENOMICS ONCOLOGY BRCAplus The Genomics product line 13 gene inherited breast cancer risk assay, where Tempus xT CDx screening and / or surgical intervention may be focuses on delivering intelligent 648-gene tissue-based NGS-based test for indicated and personalized molecular molecular profiling of a
Slide 8: Oncology testing (Tempus Genomics)
GENOMICS Oncology testing (Tempus Genomics) Our oncology product line is growing rapidly as measured by the number of tests that are ordered and delivered and the average reimbursement per test ONCOLOGY NGS - TESTS DELIVERED ONCOLOGY NGS - AVERAGE REVENUE PER TEST $1,584 $1,530 $1,452 270,800 218,70
Slide 9: Hereditary testing (Ambry Genetics) continues to demonstrate sustained volume growth
GENOMICS Hereditary testing (Ambry Genetics) continues to demonstrate sustained volume growth HEREDITARY - TESTS DELIVERED Hereditary risk represents a rapidly ~128,000 growing category, driven by: ~97,000 ● An increase in inherited cancers and NCCN guideline recommendations with testing recommended
Slide 10: Licensing
DATA Licensing We license libraries of de-identified clinical, molecular, and imaging data and provide a suite of analytic and cloud-and-compute tools through our Lens platform to pharmaceutical and biotechnology companies. Our customers leverage data across all stages of the drug development cycle,
Slide 11: We support life science companies' research needs across the product life cycle
DATA We support life science companies’ research needs across the product life cycle CLINICAL DEVELOPMENT REGULATORY MARKET ACCESS & COMMERCIALIZATION REIMBURSEMENT Identify appropriate Generate evidence to Develop a strategy to Ensure launch success comparator and support regulatory ensure product
Slide 12: Case Studies
DATA Case Studies PATIENT JOURNEY & CARE GAPS HCRU*, COST, & OUTCOMES NEW INDICATIONS & TRIAL DESIGN Quantify patient journeys in real world Quantify high-acuity HCRU & identify Uncover opportunities to address unmet settings and identify care gaps from areas to improve patient outcomes clinical nee
Slide 13: Tempus to develop largest multimodal foundation model with AstraZeneca/Pathos in oncology
DATA Tempus to develop largest multimodal foundation model with AstraZeneca/Pathos in oncology Non-exclusive collaboration allows Tempus to build other foundation models with interested parties Foundation models have the potential to unlock the Collaboration details: full potential of precision medi
Slide 14: Data & Services
DATA Data & Services Our data business continues to demonstrate robust growth based on the remaining committed total contract value (“Total Remaining Contract Value or TCV”) that is contractually committed to be delivered in the future and annual net revenue retention from customers Year End 2024 To
Slide 15: Our Apps Platform
APPS Our Apps Platform Bringing the power of AI to healthcare so millions of patients can live longer and healthier lives ● Tempus collects real-time Provider/biopharma clinical, molecular, imaging software and other data on millions of patients ● Our AI technology can enable clinical trial matching
Slide 16: Tempus AI Applications
APPS Tempus AI Applications TIME: CLINICAL TRIAL MATCHING AI-enabled clinical trial matching and just-in-time We have a suite of applications that live inside clinical trial activation in ~ 2 weeks EHRs enabling providers to leverage Tempus technology, from clinical trial matching, to care NEXT: CAR
Slide 17: AI is integrated throughout all of our products
AI is integrated throughout all of our products Allowing us to fuse insights together to create new diagnostic possibilities Hub Lens Link olivia Diagnostic ordering Cloud based data exploration Clinical trial matching and Patient application, for and resulting & analysis tool enrollment software AI
Slide 18: Financials
Financials
Slide 19: Performance summary
Q2 2025 Q2 2025 Q2 2024 Change Revenue $314.6M $166.0M 89.6% Performance Gross Profit $195.0M $75.5M 158.3% summary Loss from operations $(61.8)M $(533.5)M NM (1) Net loss $(42.8)M $(552.2)M NM (1) Adjusted EBITDA $(5.6)M $(31.2)M 82.1% Net loss per share attributable to common $(0.25) $(6.86) 96.4%
Slide 20: Summary of Results
Q2 2025 Accelerating growth, expanding margins and continued adjusted EBITDA improvement highlight underlying strength across the business Summary of Results ● Revenue increased 89.6% year-over-year to $314.6 million ● Genomics revenue of $241.8 million, growing 115.3% compared to the second quarter
Slide 21: Operational Highlights
Genomics Q2 2025 and Recent ● Introduced Tempus xM™ to monitor immune checkpoint inhibitor response in patients with advanced solid tumors for research use only, with clinical availability anticipated later in 2025 ● Expanded exclusive collaboration with Personalis to include colorectal cancer as th
Slide 22: We have achieved significant revenue scale and growth while improving profitability metrics
We have achieved significant revenue scale and growth while improving profitability metrics Our platform drives sustainable business growth. We are on track to reach our goal of positive adjusted EBITDA in 2025. REVENUE* Genomics Revenue Data & Services Revenue ADJUSTED EBITDA** $693.3M 2022 2023 2024
Slide 23: 2025 Guidance
2025 Guidance ● Our increased 2025 guidance includes ~11 months of Ambry revenue, given the acquisition closed February 3, 2025 ● We anticipate recognizing approximately $330 million, or ~$1.26 B Revenue ~26%, of our annual revenue guidance in the third quarter ~82% year-over-year ● Below are severa
Slide 24: This is the power of precision medicine. This is Tempus.
This is the power of precision medicine. This is Tempus.
Slide 25: Total Gross Profit & Gross Margin
Three months Ended June 30, Total Gross Profit & 2025 2024 Gross Margin Net Revenue $ 314,635 $ 165,969 Gross profit and gross profit margin reconciliation Cost of revenues 119,596 90,456 Gross profit $ 195,039 $ 75,513 Unaudited In thousands, except percentages Stock-based compensation expense 2,113 18
Slide 26: Non-GAAP Genomics
Three months Ended June 30, Non-GAAP 2025 2024 Genomics Revenue $241,843 $112,324 Gross profit and gross profit Cost of revenues 99,756 68,324 margin reconciliation Gross profit $ 142,087 $ 44,000 Unaudited In thousands, except percentages Stock-based compensation expense 1,420 11,327 Employer payroll
Slide 27: Non-GAAP Data and Services
Three months Ended June 30, Non-GAAP 2025 2024 Data and Services Revenue $ 72,792 $ 53,645 Gross profit and gross profit Cost of revenues 19,840 22,132 margin reconciliation Gross profit $ 52,952 $ 31,513 Unaudited In thousands, except percentages Stock-based compensation expense 693 7,229 Employer pay
Slide 28: Non-GAAP Operating expenses reconciliation
Three months Ended June 30, 2025 2024 Non-GAAP Technology R&D $ 34,482 $77,908 Stock-based compensation expense 3,285 50,434 Operating expenses Employer payroll tax related to stock-based compensation 495 1,248 reconciliation Non-GAAP technology R&D $ 30,702 $ 26,226 Research & development $ 41,619
Slide 29: Non-GAAP EPS reconciliation
Three months Ended June 30, 2025 2024 Non-GAAP Net loss $ (42,843) $(552,212) EPS reconciliation Fair value changes 1 (37,546) 4,870 Stock-based compensation expense 22,455 488,313 Employer payroll tax related to stock-based 1,873 4,762 compensation Unaudited Acquisition related expenses 2 1,992 - I
Slide 30: Adjusted EBITDA reconciliation
Three months Ended June 30, Year Ended December 31, 2025 2024 2024 2023 2022 Adjusted EBITDA Net loss $(42,843) $ (552,212) $(705,809) $(214,118) $(289,811) reconciliation Interest income (1,093) (1,718) (11,084) (7,601) (3,032) Interest expense 21,579 13,295 53,653 46,869 21,894 Depreciation 8,347